Nephropathy in a hypercholesterolemic mouse model with streptozotocin- induced diabetes

Kidney and Blood Pressure Research

Volumn 26, Issue 5-6, 2003, Pages 351-361

  Hammad, Samar M ^a   Hazen Martin, Debra J ^b   Sohn, Mimi ^a   Eldridge, Leslie ^a   Powell Braxton, Lyn ^c   Won, Wesley ^d   Lyons, Timothy J ^a,e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Amylin Pharmaceuticals Inc ^*  (United States)

^d AMYLIN PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Diabetes; Hypercholesterolemia; Hyperglycemia; Hyperlipidemia; Mouse model, diabetic nephropathy; Nephropathy; Proteinuria; Streptozotocin

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR; STREPTOZOCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLOMERULUS; HYPERCHOLESTEROLEMIA; KIDNEY DISEASE; KIDNEY PROXIMAL TUBULE; KNOCKOUT MOUSE; LIPID VESICLE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; WILD TYPE;

ALBUMINURIA; ANIMALS; ARTERIOSCLEROSIS; BASEMENT MEMBRANE; COLLAGEN; CYTIDINE DEAMINASE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; HYPERCHOLESTEROLEMIA; KIDNEY; KIDNEY TUBULES; LIPID METABOLISM; LIPIDS; MALE; MICE; MICE, KNOCKOUT; MICROSCOPY, ELECTRON; RECEPTORS, LDL; STREPTOZOCIN;

EID: 0344826683     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073942     Document Type: Article

References (40)

1. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K: 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 1990;82:27-36.
2. Bloomgarden ZT: American Diabetes Association Annual Meeting, 1999: Dyslipidemia, endothelial dysfunction, and glycosylation. Diabetes Care 2000;23:690-698.
3. Coonrod BA, Ellis D, Becker DJ, Bunker CH, Kelsey SF, Lloyd CE, Drash AL, Kuller LH, Orchard TJ: Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 1993;16:1376-1383.
4. Grone EF, Walli AK, Grone HJ, Miller B, Seidel D: The role of lipids in nephrosclerosis and glomerulosclerosis. Atherosclerosis 1994;107: 1-13.
5. Ellis D, Lloyd C, Becker DJ, Forrest KY, Orchard TJ: The changing course of diabetic nephropathy: Low-density lipoprotein cholesterol and blood pressure correlate with regression of proteinuria. Am J Kidney Dis 1996;27:809-818.
6. Lam KS, Cheng IK, Janus ED, Pang RW: Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995;38:604-609.
7. Ishibashi S, Brown MS, Goldstein JL, Gerard RD, Hammer RE, Herz J: Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993;92: 883-893.
8. Kunjathoor VV, Wilson DL, LeBoeuf RC: Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 1996;97: 1767-1773.
9. Reaven P, Merat S, Casanada F, Sutphin M, Palinski W: Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 1997;17:2250-2256.
10. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end-products. Nat Med 1998;4:1025-1031.
11. Keren P, George J, Shaish A, Levkovitz H, Janakovic Z, Afek A, Goldberg I, Kopolovic J, Keren G, Harats D: Effect of hyperglycemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient mice: Establishment of a combined model and association with heat shock protein 65 immunity. Diabetes 2000;49: 1064-1069.
12. Kako Y, Masse M, Huang LS, Tall AR, Goldberg IJ: Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. J Lipid Res 2002;43:872-877.
13. Powell-Braxton L, Veniant M, Latvala RD, Hirano KI, Won WB, Ross J, Dybdal N, Zlot CH,Young SG, Davidson NO: A mouse model of human familial hypercholesterolemia: Markedly elevated low-density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nat Med 1998;4:934-938.
14. Farese RV Jr, Veniant MM, Cham CM, Flynn LM, Pierotti V, Loring JF, Traber M, Ruland S, Stokowski RS, Huszar D, Young SG: Phenotypic analysis of mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. Proc Natl Acad Sci U S A 1996;93:6393-6398.
15. Nakamuta M, Taniguchi S, Ishida BY, Kobayashi K, Chan L: Phenotype interaction of apobec-1 and CETP, LDLR, and apoE gene expression in mice: Role of apoB mRNA editing in lipoprotein phenotype expression. Arterioscler Thromb Vasc Biol 1998;18:747-755.
16. Hammad SM, Siegel HS, Marks HL: Total cholesterol, total triglycerides, and cholesterol distribution among lipoproteins as predictors of atherosclerosis in selected lines of Japanese quail. Comp Biochem Physiol A Mol Integr Physiol 1998;119:485-492.
17. Wasan KM, Najafi S, Wong J, Kwong M, Pritchard PH: Assessing plasma lipid levels, body weight, and hepatic and renal toxicity following chronic oral administration of a water soluble phytostanol compound, FM-VP4, to gerbils. J Pharm Pharm Sci 2001;4:228-234.
18. Cohen MP, Sharma K, Jin Y, Hud E, Wu VY, Tomaszewski J, Ziyadeh FN: Prevention of diabetic nephropathy in db/db mice with glycated albumin antagonists: A novel treatment strategy. J Clin Invest 1995;95:2338-2345.
19. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC: Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74:1143-1155.
20. Fioretto P, Steffes MW, Mauer M: Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994;43:1358-1364.
21. Brito PL, Fioretto P, Drummond K, Kim Y, Steffes MW, Basgen JM, Sisson-Ross S, Mauer M: Proximal tubular basement membrane width in insulin-dependent diabetes mellitus. Kidney Int 1998;53:754-761.
22. Tryggvason K, Wartiovaara J: Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 2001;10:543-549.
23. Galaske RG, Gartner K, Stolte H: Functional and morphological study on the onset of proteinuria in experimental diabetes mellitus. Contrib Nephrol 1975;1:69-79.
24. Tsutsumi K, Hagi A, Inoue Y: The relationship between plasma high density lipoprotein cholesterol levels and cholesteryl ester transfer protein activity in six species of healthy experimental animals. Biol Pharm Bull 2001;24:579-581.
25. Hammad SM, Powell-Braxton L, Otvos JD, Eldridge L, Won W, Lyons TJ: Lipoprotein subclass profiles of hyperlipidemic diabetic mice measured by nuclear magnetic resonance spectroscopy. Metabolism 2003;52:916-921.
26. Otvos J, Jeyarajah E, Bennett D: A spectroscopic approach to lipoprotein subclass analysis. J Clin Ligand Assay 1996;19:184-189.
27. Lyons TJ, Jenkins AJ, Zheng D, Otvos JD, Klein RL, Lackland DT, McGee D, Garvey WT, The DCCT/EDIC Research Group: Serum lipoproteins in the DCCT/EDIC Cohort: Associations with diabetic retinopathy. Invest Ophthalmol Vis Sci, in press.
28. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Klein RL, Lackland DT, McGee D, Garvey WT, The DCCT/EDIC Research Group: Serum lipoproteins in the DCCT/EDIC Cohort: Associations with diabetic nephropathy. Kidney Int, in press.
29. Sibley SD, Hokanson JE, Steffes MW, Purnell JQ, Marcovina SM, Cleary PA, Brunzell JD: Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care 1999;22:1165-1170.
30. Superko HR: New aspects of risk factors for the development of atherosclerosis, including small dense lipoprotein, homocyst(e)ine, and lipoprotein(a). Curr Opin Cardiol 1995;10: 347-354.
31. Gardner CD, Fortmann SP, Krauss RM: Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-881.
32. Lamauche B, Tchernof A, Mourjani S, Cantin B, Dagenais GR, Lupin PJ, Dispers JP: Small, dense, low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95: 69-75.
33. Eckardstein A, Huang Y, Assmann G: Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 1994;5:404-416.
34. Hansen PR: Cholesterol ester transfer protein: A major player in cholesterol metabolism. Ugeskr Laeger 1999;161:5295-5298.
35. Francone OL, Royer L, Haghpassand M: Increased prebeta-HDL levels, cholesterol efflux, and LCAT-mediated esterification in mice expressing the human cholesteryl ester transfer protein (CETP) and human apolipoprotein A-I (apoA-I) transgenes. J Lipid Res 1996;37: 1268-1277.
36. Tolins JP, Stone BG, Raij L: Interactions of hypercholesterolemia and hypertension in initiation of glomerular injury. Kidney Int 1992; 41:1254-1261.
37. Grone HJ, Hohbach J, Grone EF: Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins. Kidney Int Suppl 1996;54:S18-S22.
38. Scheuer H, Gwinner W, Hohbach J, Grone EF, Brandes RP, Malle E, Olbricht CJ, Walli AK, Grone HJ: Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Renal Physiol 2000;278:F63-F74.
39. Galeano NF, Milne R, Marcel YL, Walsh MT, Levy E, Ngu'yen TD, Gleeson A, Arad Y, Witte L, al-Haideri M: Apoprotein B structure and receptor recognition of triglyceride-rich low-density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J Biol Chem 1994;269:511-519.
40. Nigon F, Lesnik P, Rouis M, Chapman MJ: Discrete subspecies of human low-density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991;32:1741-1753.